Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Melanoma treatment details. Biologic therapy. Seattle Cancer Care Alliance, Seattle, WA, United States



Survival: 7.0 months
   
Toxicity Grade: 4
   
Treatments: Biologic therapy
   
Drugs:
Country: United States
   
City/State/Province: Seattle, WA
   
Hospital: Seattle Cancer Care Alliance
   
Journal: Link
   
Date: 2/2012

Description:
Patients:
This phase II study involved untreated metastatic melanoma patients who were separated into two separate treatment groups. Group A consisted of 63 patients with a median age of 64.5 years and 54% male. Group B had 39 patients with a median age of 58 years and 56% male.

Treatment:
Patients in group A were treated with the biologic therapy agents sorafenib and temsirolimus, both of which are angiogenesis inhibitors that inhibit blood supply to tumors.

Patients in group B were treated with the biologic therapy agents sorafenib and tipifarnib, which is also an angiogenesis inhibitor.

Toxicities:
There were two treatment-related deaths due to pneumonia and pancreatitis in group A. Grade 3-4 fatigue, rash, and diarrhea were also reported.

The most severe treatment-related toxicity in group B was of grade 4, including grade 3-4 hand-foot skin reaction and acne.

Results:
The median overall survival for both group A and group B was 7.0 monhth.

Support:
Some of the authors of the study have received support from several pharmaceutical companies.

Correspondence: Dr. Kim A. Margolin; email: kmargoli@seattlecca.org

E-mail to a Friend Email Physician More Information